BamSEC and AlphaSense Join Forces
Learn More

Theravance Biopharma Inc. – Material Contracts

NASDAQ: TBPH    
Share price (8/24/26): $17.01    
Market cap (8/24/26): $883 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 10-Q 1 page Certain Personally Identifiable Information Has Been Omitted From This Exhibit Pursuant to Item 601(a)(6) of Regulation S-K. the Omitted Information Is Indicated by “[***].” ​ Strictly Private & Confidential Addressee Only ​ Áine Miller [***] ​ Re: Special Employer Pension Contribution 18 June 2026 Dear Áine,
12/34/56
EX-10.1
from 10-Q 8 pages Certain Personally Identifiable Information Has Been Omitted From This Exhibit Pursuant to Item 601(a)(6) of Regulation S-K. the Omitted Information Is Indicated by “[***].” ​ Strictly Private & Confidential Addressee Only ​ Áine Miller [***] ​ 18 June 2026 ​ Dear Áine, ​ Further to My Letter Dated 13 March 2026, I Now Wish to Confirm the Severance Terms on Offer to You and the Conditions for Acceptance of Same. ​ This Letter ​
12/34/56
EX-10.1
from 10-Q 5 pages February 8, 2026 ​ by Email ​ Dr. Aine Miller ​ Re:your Employment Contract Dated 10 February 2020 ​ Dear Dr. Miller I Refer to Your Contract of Employment Dated 10 February 2020 With Theravance Biopharma Ireland Limited (The “Company”). the Purpose of This Letter Is to Amend This Contract by the Addition of the Following Clause 28: 28. Severance Upon Termination Without Misconduct
12/34/56
EX-10.8
from 10-K 3 pages Theravance Biopharma, Inc. Amended and Restated 2013 Equity Incentive Plan (“The Plan”) ​ Irish Addendum
12/34/56
EX-10.19
from 10-K 14 pages Theravance Biopharma, Inc. Executive Severance Plan and Summary Plan Description ​
12/34/56
EX-10.3
from 10-Q 22 pages Employment Contract of Indefinite Duration
12/34/56
EX-10.2
from 10-Q 7 pages Separation Agreement and Release of Claims
12/34/56
EX-10.1
from 10-Q 4 pages Theravance Biopharma Inc. Amended and Restated 2013 Equity Incentive Plan Restricted Share Purchase Agreement
12/34/56
EX-10.39
from 10-K 3 pages June 12, 2018 Revised Offer Rhonda F. Farnum [Address] Dear Rhonda
12/34/56
EX-10.1
from 8-K 27 pages Cooperation Agreement
12/34/56
EX-10.3
from 10-Q 7 pages Theravance Biopharma, Inc. 2013 Equity Incentive Plan Notice of Restricted Share Unit Award
12/34/56
EX-10.2
from 10-Q 2 pages [Theravance Biopharma Company Logo] ​ June 16, 2014 ​ Aziz Sawaf ​ Dear Aziz: ​
12/34/56
EX-10.1
from 10-Q 5 pages ​ [Theravance Biopharma Company Logo] ​ May 12, 2014 ​ Brett Grimaud ​ Dear Brett: ​
12/34/56
EX-10.1
from 8-K 17 pages Amended and Restated 2013 Equity Incentive Plan Theravance Biopharma, Inc. 2013 Equity Incentive Plan (Originally Adopted Effective October 22, 2013, Amended & Restated Effective February 14, 2023) 1
12/34/56
EX-10.77
from 10-K 8 pages Separation Agreement and Release of Claims
12/34/56
EX-10.72
from 10-K 14 pages To the Members and the Board of Directors of Theravance Respiratory Company, LLC Opinion on the Financial Statements
12/34/56
EX-10.4
from 10-Q 2 pages First Amendment to the Theravance Biopharma, Inc. Change in Control Severance Plan ​
12/34/56
EX-10.2
from 8-K 8 pages Release Agreement
12/34/56
EX-10.1
from 8-K 43 pages Master Consent
12/34/56
EX-10.72
from 10-K 14 pages To the Members and the Board of Directors of Theravance Respiratory Company, LLC Opinion on the Financial Statements
12/34/56